- Which of the following is the most appropriate test to confirm H. pylori eradication?
Answer: Urea breath test
The urea breath test and the stool antigen test are the preferred non-invasive methods for confirming H. pylori eradication. These tests detect active infection. They should be performed at least 4 weeks after completion of antibiotic therapy and after proton pump inhibitors have been held for 1-2 weeks. Since the patient is asymptomatic and off medications, the urea breath test is an excellent choice.
* **A) H. pylori serology (IgG):** Serology tests for IgG antibodies against H. pylori. These antibodies can remain elevated for months to years even after successful eradication and therefore cannot be used to confirm cure.
* C) Repeat upper endoscopy with biopsy: This is an invasive method and is not necessary for confirming eradication in an asymptomatic patient with an uncomplicated ulcer. It is reserved for patients with complicated ulcers (e.g., bleeding, gastric ulcer) to ensure healing and rule out malignancy.
* D) Fecal calprotectin: This is a marker for intestinal inflammation, primarily used in the diagnosis and monitoring of inflammatory bowel disease, not for H. pylori testing.
- Which diagnostic study is most appropriate next to differentiate primary achalasia from malignancy-related pseudoachalasia?
Answer: Upper endoscopy with careful inspection and tissue biopsy of the gastroesophageal junction
When you encounter a patient with dysphagia and the classic "bird's beak" appearance on barium swallow, you're dealing with either primary achalasia or pseudoachalasia (secondary achalasia). The key clinical challenge is distinguishing between these two conditions, especially in older patients where malignancy becomes a significant concern.
Upper endoscopy with careful inspection and tissue biopsy of the gastroesophageal junction (A) is the most appropriate next step because it directly visualizes the area and can identify infiltrating malignancies that cause pseudoachalasia. Gastric adenocarcinoma, esophageal cancer, and other tumors can invade the gastroesophageal junction and mimic primary achalasia by causing functional obstruction.
High-resolution esophageal manometry (B) is excellent for confirming achalasia and subtyping it, but it cannot differentiate between primary achalasia and malignancy-related pseudoachalasia since both conditions show impaired lower esophageal sphincter relaxation. CT scan with contrast (C) might identify extrinsic masses causing compression, but most cases of pseudoachalasia result from infiltrating tumors rather than external compression, making endoscopy more sensitive. Timed barium esophagram (D) measures functional impairment but doesn't help distinguish the underlying cause.
The age of this patient (70 years old) is particularly important—pseudoachalasia from malignancy is more common in patients over 60, while primary achalasia typically presents earlier. Remember: when achalasia presents in older adults, always rule out malignancy first with endoscopy and biopsy before proceeding with achalasia-specific treatments like pneumatic dilation or peroral endoscopic myotomy.
- Which strategy best minimizes his risk of another NSAID-related ulcer bleed while allowing continued anti-inflammatory therapy?
Answer: Switch to a selective COX-2 inhibitor and add once-daily proton pump inhibitor therapy
When managing a patient who requires NSAIDs but has a history of GI bleeding, you need to balance effective pain control with gastroprotection. This scenario tests your understanding of evidence-based strategies for high-risk patients.
The optimal approach combines two protective mechanisms: using a COX-2 selective inhibitor (which has lower GI toxicity than traditional NSAIDs) plus adding a proton pump inhibitor for acid suppression. This dual strategy provides the strongest protection against recurrent ulcer bleeding while maintaining anti-inflammatory efficacy. COX-2 inhibitors selectively block the inflammatory pathway while preserving protective prostaglandins in the GI tract, and PPIs dramatically reduce gastric acid production.
Looking at the wrong choices: B) Sucralfate provides only modest gastroprotection compared to PPIs and doesn't address the inherent ulcerogenic properties of naproxen, a traditional NSAID. C) High-dose acetaminophen (3g daily) lacks anti-inflammatory properties needed for osteoarthritis and poses hepatotoxicity risks, especially in elderly patients. D) Misoprostol alone, while gastroprotective through prostaglandin replacement, doesn't eliminate the COX-1 inhibition from continued NSAID use and often causes intolerable diarrhea at effective doses.
For Step 2 CK, remember that patients with prior GI bleeding on NSAIDs are considered very high-risk and require maximum protection. The combination of COX-2 inhibitor plus PPI is the gold standard approach. Watch for questions that test whether you know to use both strategies together rather than relying on a single intervention.
- Which of the following is the most likely cause of his cough?
Answer: Gastroesophageal reflux disease
Chronic cough, laryngitis, and globus sensation are well-recognized extraesophageal manifestations of gastroesophageal reflux disease (GERD). This is often termed 'silent reflux' or laryngopharyngeal reflux (LPR) because classic symptoms like heartburn may be absent. Given that other common causes of chronic cough (post-nasal drip, asthma) have been empirically treated without success, GERD becomes a leading diagnosis. The bitter taste in his mouth further supports reflux as the etiology. The next step would be an empiric trial of high-dose PPI therapy.
* A) Chronic bronchitis: This is defined by a productive cough for at least 3 months in 2 consecutive years and is strongly associated with smoking. This patient has a non-productive cough.
* B) Angiotensin-converting enzyme inhibitor side effect: This is a common cause of dry cough, but the patient is not described as taking an ACE inhibitor.
* D) Post-nasal drip syndrome: This typically presents with a sensation of mucus dripping down the back of the throat and frequent throat clearing. The patient has already been treated for this without improvement.
- A 52-year-old woman presents with epigastric pain relieved by meals and awakening her at night. She takes no NSAIDs and H. pylori testing is negative. After 8 weeks of standard-dose PPI therapy she still has symptoms. Which is the most appropriate next diagnostic step?
Answer: Upper endoscopy to evaluate for non-*H. pylori*, non-NSAID ulcer and other pathology
When a patient has persistent dyspeptic symptoms despite adequate PPI therapy, you need to systematically evaluate for underlying pathology that requires direct visualization or alternative diagnoses.
This patient presents with classic peptic ulcer symptoms (epigastric pain relieved by meals, nocturnal awakening) but has failed standard therapy after excluding the two most common causes: H. pylori and NSAIDs. The 8-week duration of appropriate PPI treatment makes simple acid-related disease unlikely to be the sole cause. At this point, direct visualization becomes essential to identify other serious conditions.
Upper endoscopy (A) is correct because it can diagnose non-*H. pylori*, non-NSAID ulcers (which may have different underlying causes like Zollinger-Ellison syndrome), gastric cancer, or other mucosal abnormalities that won't respond to acid suppression alone. This represents the standard of care for PPI-refractory dyspepsia.
Adding bismuth subsalicylate (B) is inappropriate without knowing what you're treating - there's no evidence of H. pylori infection that would justify empiric combination therapy. Abdominal ultrasound (C) could detect gallstones, but this patient's symptom pattern (meal relief rather than meal precipitation) and epigastric location don't suggest biliary pathology. Celiac testing (D) doesn't match the clinical presentation, as celiac disease typically causes diarrhea, bloating, and weight loss rather than ulcer-like pain.
Key strategy: When standard therapy fails for peptic symptoms, endoscopy is almost always the next step. Don't keep throwing medications at undiagnosed conditions - visualize the problem first.
- When should his aspirin therapy be resumed?
Answer: Within 3–5 days once hemostasis is secured because of cardiovascular benefit
When you encounter questions about restarting antiplatelet therapy after GI bleeding, you need to balance bleeding risk against thrombotic risk. This patient has coronary artery disease requiring secondary prevention, making aspirin discontinuation potentially life-threatening.
The correct approach is to resume aspirin within 3-5 days once hemostasis is secured (Answer A). Studies show that early aspirin resumption (within 3-7 days) significantly reduces cardiovascular events without substantially increasing rebleeding risk, especially when endoscopic hemostasis has been achieved. The cardiovascular benefit outweighs the small increased bleeding risk in patients requiring secondary prevention.
Answer B is incorrect because waiting 8 weeks creates an unacceptably high risk of cardiovascular events. While PPI therapy should continue for ulcer healing, aspirin resumption doesn't need to wait for complete ulcer healing when hemostasis is secure.
Answer C represents a dangerous misconception. While aspirin may contribute to bleeding risk, permanently discontinuing it in a patient with established coronary disease dramatically increases their risk of MI, stroke, and cardiovascular death. The absolute cardiovascular risk far exceeds the rebleeding risk.
Answer D is wrong because immediate resumption doesn't allow confirmation of hemostasis, and adding clopidogrel increases bleeding risk without clear benefit in this scenario. Dual antiplatelet therapy isn't indicated based on the information provided.
Remember this key principle: In patients requiring antiplatelet therapy for secondary cardiovascular prevention, early resumption (3-5 days) after achieving endoscopic hemostasis optimizes the risk-benefit ratio. Never permanently discontinue essential cardioprotective medications without considering alternative strategies.
- Which of the following is the most appropriate pharmacologic therapy to initiate immediately after endoscopy?
Answer: Intravenous proton pump inhibitor bolus followed by continuous infusion for 72 hours
When you encounter upper GI bleeding with high-risk endoscopic features like active arterial bleeding (Forrest Ia), your immediate post-procedural management focuses on preventing rebleeding through aggressive acid suppression.
Choice A is correct because high-dose IV proton pump inhibitor (PPI) therapy represents the gold standard for post-endoscopic management of high-risk peptic ulcer bleeding. The regimen typically involves an 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours. This aggressive acid suppression maintains gastric pH above 6, which stabilizes clot formation and prevents pepsin-mediated clot dissolution. Multiple randomized trials have demonstrated that this approach significantly reduces rebleeding rates, need for surgery, and mortality in patients with high-risk stigmata.
Choice B is incorrect because sucralfate, while cytoprotective, provides inadequate acid suppression for high-risk bleeding ulcers and is considered inferior to PPIs in this setting. Choice C is wrong because H2 receptor antagonists, even at high doses, cannot achieve the sustained profound acid suppression that PPIs provide and are associated with higher rebleeding rates. Choice D represents poor timing because while H. pylori eradication is ultimately important for preventing ulcer recurrence, it should be delayed until after the acute bleeding episode is managed, and acid suppression is essential during the high-risk rebleeding period.
Remember: For high-risk peptic ulcer bleeding (Forrest Ia or Ib lesions), think "PPI first, everything else later." The 72-hour IV PPI protocol is your immediate priority, with H. pylori testing and eradication planned for after stabilization.
- In a 55-year-old man with chronic gastroesophageal reflux disease and newly diagnosed nondysplastic Barrett esophagus (C2M3 Prague classification), which surveillance strategy is most consistent with guideline recommendations?
Answer: Repeat upper endoscopy every 3–5 years with four-quadrant biopsies every 2 cm of the Barrett segment
Barrett esophagus surveillance questions test your knowledge of evidence-based guidelines for cancer prevention. When you encounter Barrett esophagus scenarios, focus on the presence or absence of dysplasia and the appropriate surveillance intervals.
For nondysplastic Barrett esophagus, current guidelines recommend surveillance endoscopy every 3-5 years with systematic four-quadrant biopsies every 2 cm throughout the Barrett segment. The Prague classification helps standardize the extent of Barrett tissue (C = circumferential extent, M = maximal extent), but doesn't change surveillance recommendations for nondysplastic disease. This approach balances cancer detection with cost-effectiveness and patient burden.
Choice B is incorrect because annual surveillance is too frequent for nondysplastic Barrett esophagus and would lead to overuse of resources. While narrow-band imaging can enhance visualization, it doesn't replace the standard surveillance interval. Choice C represents a dangerous misconception—nondysplastic Barrett esophagus still carries malignant potential and requires ongoing surveillance, as dysplasia can develop over time. Choice D is inappropriate because radiofrequency ablation is reserved for dysplastic Barrett esophagus, not nondysplastic disease. Treatment of nondysplastic Barrett with ablation isn't recommended due to insufficient evidence of benefit and potential procedural risks.
Remember that Barrett esophagus surveillance intervals depend entirely on histology: nondysplastic disease requires surveillance every 3-5 years, while dysplastic disease requires more frequent monitoring or treatment. Always match the surveillance intensity to the dysplasia grade rather than the extent of Barrett tissue.
- What is the next best step in management?
Answer: Increase the proton pump inhibitor to twice-daily dosing before breakfast and dinner
When managing GERD that's inadequately controlled on standard PPI therapy, you need to optimize medical management before considering invasive testing or procedures. This patient has persistent symptoms on once-daily omeprazole despite proper timing (30 minutes before meals), indicating the need for dose escalation.
The correct approach is A) Increase the proton pump inhibitor to twice-daily dosing before breakfast and dinner. Standard PPI therapy fails in about 20-40% of GERD patients, and twice-daily dosing is the next logical step. This provides better acid suppression throughout the day, particularly for patients with breakthrough symptoms. The timing before meals optimizes PPI effectiveness since these medications work best when proton pumps are actively functioning.
B) Ambulatory impedance-pH monitoring is premature here. You'd only consider this after optimizing PPI therapy fails, to assess for non-acid reflux or confirm true PPI-refractory disease.
C) Laparoscopic Nissen fundoplication is far too aggressive without exhausting medical options first. Surgery is reserved for patients who fail optimal medical therapy or have complications.
D) Immediate upper endoscopy isn't indicated since the patient lacks alarm symptoms (dysphagia, weight loss, bleeding). While Barrett esophagus screening may eventually be appropriate given her chronic symptoms, symptom control takes priority, and endoscopy can be scheduled electively if medical optimization fails.
Key strategy: Always optimize medical management before pursuing invasive interventions in GERD. The step-wise approach is: standard PPI → twice-daily PPI → specialized testing → consider surgery.
- Which of the following is the most likely diagnosis?
Answer: Achalasia
This patient's presentation of progressive dysphagia to both solids and liquids, regurgitation of undigested food, and weight loss is classic for achalasia. Achalasia is a primary esophageal motility disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and loss of peristalsis in the distal esophagus. The barium esophagram finding of a dilated esophagus with a 'bird's beak' appearance at the gastroesophageal junction is pathognomonic.
* A) Schatzki ring: This is a type of esophageal stricture that causes intermittent, non-progressive dysphagia to solids only, not liquids.
* B) Eosinophilic esophagitis: This condition can cause dysphagia to solids, often with food impaction, but dysphagia to liquids is less common. It typically affects younger men with a history of atopy.
* D) Scleroderma esophagus: This condition involves smooth muscle atrophy and fibrosis, leading to an incompetent LES and absent peristalsis. While it causes dysphagia, it is more characteristically associated with severe, refractory GERD symptoms, which this patient denies.
- Which of the following is the most likely diagnosis?
Answer: Duodenal ulcer
The clinical presentation is classic for a duodenal ulcer. Key features include epigastric pain that improves with food intake and worsens 2-3 hours postprandially (when the gastric acid load enters the duodenum without a food buffer). Nocturnal pain is also a common feature, as circadian acid secretion is highest at night. In contrast, pain from a gastric ulcer typically worsens with eating.
* A) Gastric ulcer: The pain of a gastric ulcer is classically exacerbated by eating, as food stimulates acid secretion that irritates the ulcerated gastric mucosa.
* C) Gastroesophageal reflux disease: GERD typically causes a burning retrosternal pain (heartburn) that is worse with lying down or after certain foods, not pain that is relieved by eating.
* D) Chronic pancreatitis: This usually causes persistent epigastric pain that radiates to the back and is often associated with malabsorption (steatorrhea, weight loss) and a history of recurrent acute pancreatitis or alcohol abuse.
- Which of the following is the most appropriate next step in the management of this patient?
Answer: Perform upper endoscopy
This patient presents with several alarm features for esophageal malignancy: progressive dysphagia (solids more than liquids), significant unintentional weight loss, and age >50. Additionally, his smoking and alcohol history are significant risk factors for squamous cell carcinoma of the esophagus. The presence of these alarm features warrants prompt investigation to rule out malignancy. Upper endoscopy (EGD) with biopsy is the diagnostic test of choice in this setting as it allows for direct visualization and tissue sampling.
* A) Initiate a trial of a proton pump inhibitor: While GERD can cause strictures, the alarm features in this patient make a simple PPI trial inappropriate and potentially dangerous due to the delay in diagnosing a possible cancer.
* C) Order a barium esophagram: A barium swallow can identify a stricture or mass, but it cannot differentiate between benign and malignant causes and does not allow for biopsy. Endoscopy would still be required for a definitive diagnosis.
* D) Perform esophageal manometry: Manometry is used to evaluate esophageal motility disorders like achalasia or diffuse esophageal spasm. This patient's progressive dysphagia to solids suggests a mechanical obstruction, not a motility disorder.
- Which of the following is the most appropriate initial step in management?
Answer: Lifestyle modifications and a trial of a proton pump inhibitor
This patient presents with classic symptoms of uncomplicated gastroesophageal reflux disease (GERD): postprandial and nocturnal heartburn, and regurgitation. He is under 50 years old and has no alarm features (e.g., dysphagia, weight loss, anemia, hematemesis). Therefore, the most appropriate initial management is an empiric trial of a proton pump inhibitor (PPI) along with counseling on lifestyle modifications, such as weight loss, dietary changes, and elevating the head of the bed.
* A) Upper endoscopy: Endoscopy is not indicated as a first step for typical GERD symptoms in the absence of alarm features.
* B) 24-hour esophageal pH monitoring: This is the gold standard for diagnosing GERD but is reserved for patients with atypical symptoms or those who fail to respond to an empiric trial of PPIs.
* D) Barium esophagram: This test has low sensitivity for GERD and is primarily used to evaluate for structural abnormalities like strictures or hiatal hernias when dysphagia is present.
- What is the most appropriate definitive treatment for her condition?
Answer: Endoscopic esophageal dilation with subsequent proton pump inhibitor therapy
When you encounter dysphagia with specific findings on barium swallow, focus on identifying the underlying pathology to guide treatment selection. This case describes a Schatzki ring (B-ring) - a thin, circumferential mucosal ring at the gastroesophageal junction that causes intermittent solid food dysphagia, especially with dense foods like steak.
The correct answer is A because Schatzki rings are best treated with endoscopic dilation to fracture the ring, followed by proton pump inhibitor (PPI) therapy to reduce acid reflux that contributes to ring formation. This approach addresses both the mechanical obstruction and the underlying inflammatory process. The dilation provides immediate relief, while PPIs prevent recurrence by controlling gastroesophageal reflux disease (GERD).
Option B (botulinum toxin) is used for achalasia, which presents with progressive dysphagia to both solids and liquids, not the intermittent solid-only dysphagia seen here. Option C (nitrates/calcium channel blockers) are also achalasia treatments that reduce lower esophageal sphincter pressure - unnecessary since Schatzki rings don't involve sphincter dysfunction. Option D (surgical myotomy) is the definitive treatment for achalasia or severe motility disorders, not structural rings.
Key strategy: Distinguish between mechanical obstruction (Schatzki ring) and functional disorders (achalasia). Intermittent solid-only dysphagia with a thin mucosal ring on imaging points to Schatzki ring, while progressive dysphagia to solids and liquids suggests achalasia. Match the pathophysiology to the appropriate intervention - mechanical problems need mechanical solutions (dilation), while motility disorders need treatments that affect muscle function.
- Which is the most appropriate initial diagnostic test?
Answer: Contrast esophagram using water-soluble (gastrografin) contrast medium
When you encounter a patient with forceful vomiting followed by severe chest pain and subcutaneous emphysema, think Boerhaave syndrome - a full-thickness esophageal rupture. This is a surgical emergency requiring immediate diagnosis and intervention.
The combination of retching, retrosternal pain radiating to the back, and subcutaneous emphysema (indicating air leak from the esophagus into surrounding tissues) creates a classic triad for esophageal rupture. The key diagnostic challenge is confirming the rupture and identifying its location for surgical planning.
Choice A is correct because water-soluble contrast esophagram is the gold standard initial test for suspected esophageal rupture. Gastrografin contrast will extravasate through the rupture site, clearly demonstrating the tear's location and extent. Water-soluble contrast is safer than barium if aspiration occurs, and the study can be performed quickly.
Choice B is dangerous - endoscopy risks extending the tear by insufflating air and can worsen mediastinal contamination. It's contraindicated in suspected full-thickness rupture.
Choice C might show mediastinal air, but this finding alone doesn't confirm esophageal rupture (could be from other causes) and doesn't localize the tear for surgical repair.
Choice D addresses the differential diagnosis of chest pain, but the clinical picture strongly suggests esophageal pathology rather than cardiac. The subcutaneous emphysema is the key distinguishing feature that makes MI unlikely.
Remember: Boerhaave syndrome after vomiting + subcutaneous emphysema = immediate water-soluble contrast study. Time is critical as delayed diagnosis significantly increases mortality.
- Which of the following is the most appropriate management?
Answer: Admit for observation and supportive care
This patient's history of forceful vomiting followed by hematemesis, along with the endoscopic finding of a linear tear at the GE junction, is diagnostic of a Mallory-Weiss tear. The vast majority (>80-90%) of these tears stop bleeding spontaneously and do not require endoscopic or surgical intervention. Since the patient is hemodynamically stable and the tear is not actively bleeding on endoscopy, the most appropriate management is admission for observation and supportive care (e.g., antiemetics, acid suppression if needed). Most patients can be discharged within 24-48 hours.
* A) Endoscopic band ligation: This is a treatment for bleeding esophageal varices, not Mallory-Weiss tears.
* B) Initiate high-dose intravenous proton pump inhibitor: While a PPI may be given, it is not the primary intervention. The key is that active intervention is not needed for a non-bleeding tear. Supportive care is the cornerstone of management.
* D) Refer for emergent surgical repair: Surgery is reserved for rare cases of massive, uncontrolled bleeding from a Mallory-Weiss tear that has failed endoscopic therapy.
- Which of the following is the most appropriate next step?
Answer: Perform upper endoscopy
This patient has symptoms of GERD that are refractory to an adequate trial of once-daily proton pump inhibitor (PPI) therapy. Failure to respond to standard-dose PPI therapy is an indication for further investigation to confirm the diagnosis, evaluate for complications of GERD (e.g., esophagitis, stricture), and rule out alternative diagnoses (e.g., eosinophilic esophagitis, achalasia). Therefore, upper endoscopy is the most appropriate next step.
* A) Increase omeprazole to 40 mg twice daily: While optimizing PPI therapy is a management option, it is generally done after an underlying cause for refractory symptoms has been investigated. An endoscopy is needed to rule out complications or an alternative diagnosis before simply increasing the dose.
* B) Add an H2 receptor antagonist at bedtime: This can be a strategy for nocturnal acid breakthrough but is less effective than optimizing PPI therapy and does not address the need for a diagnostic evaluation in refractory GERD.
* D) Refer for anti-reflux surgery: Surgery is considered for patients with confirmed GERD who are intolerant to or do not wish to take long-term PPIs, or who have complications like a large hiatal hernia. It is not appropriate before a definitive diagnosis is confirmed and other causes are excluded.
- Which of the following is the most important additional recommendation for this patient?
Answer: Discontinue naproxen
The patient has an *H. pylori*-negative gastric ulcer, and her daily use of naproxen, a non-steroidal anti-inflammatory drug (NSAID), is the most likely cause. NSAIDs inhibit prostaglandin synthesis, which compromises the protective gastric mucosal barrier. The most critical step in managing an NSAID-induced ulcer is to discontinue the offending agent, if clinically feasible. Healing is significantly delayed if the NSAID is continued, even with aggressive acid suppression therapy.
* B) Start sucralfate therapy: Sucralfate can provide a protective coating over the ulcer but is considered an adjunctive therapy. The primary intervention is removing the cause (NSAID) and suppressing acid (PPI).
* C) Repeat endoscopy in 2 weeks: A repeat endoscopy is necessary to ensure healing of a gastric ulcer (to rule out malignancy), but it is typically performed in 8-12 weeks, not 2 weeks. The immediate priority is stopping the NSAID.
* D) Test for serum gastrin level: This is done to screen for Zollinger-Ellison syndrome, which is a rare cause of PUD. It would be considered if the ulcer is refractory to treatment or if there are multiple ulcers, but NSAID-induced ulcer is far more likely in this patient.
- Which of the following is the most appropriate next step in management?
Answer: Start an intravenous infusion of a high-dose proton pump inhibitor
This patient had an ulcer with a high-risk stigmata of rebleeding (active arterial spurting). After successful endoscopic therapy for such high-risk ulcers, patients should be treated with a continuous intravenous infusion of a high-dose proton pump inhibitor (e.g., pantoprazole 80 mg bolus followed by 8 mg/hr infusion) for 72 hours. This intensive acid suppression promotes clot stability and has been shown to significantly reduce the rates of rebleeding, need for surgery, and mortality.
* A) Discharge home on an oral proton pump inhibitor: Discharging the patient is inappropriate given the high risk of rebleeding. He requires inpatient monitoring and IV therapy.
* B) Initiate a continuous infusion of intravenous octreotide: Octreotide is a somatostatin analog used to reduce splanchnic blood flow in the management of variceal hemorrhage, not non-variceal bleeding like PUD.
* D) Arrange for transarterial embolization within 24 hours: Transarterial embolization is a second-line therapy reserved for patients who have recurrent bleeding despite endoscopic treatment or in whom endoscopic therapy fails.
- Which of the following is the most likely source of his bleeding?
Answer: Esophageal varices
In a patient with known cirrhosis and signs of portal hypertension (ascites), esophageal varices are the most common and most feared cause of massive upper gastrointestinal bleeding. Portal hypertension leads to the formation of portosystemic collaterals, including fragile, dilated submucosal veins in the distal esophagus and proximal stomach that are prone to rupture and life-threatening hemorrhage. While PUD is the most common cause of UGIB in the general population, varices are the most likely cause in this specific clinical context.
* B) Mallory-Weiss tear: This is a mucosal tear at the gastroesophageal junction caused by forceful retching or vomiting. It is a possible cause but less likely to cause such profound hemodynamic instability compared to a variceal bleed in a cirrhotic patient.
* C) Dieulafoy's lesion: This is a rare cause of UGIB resulting from a large, tortuous arteriole in the stomach wall that erodes through the mucosa. It can cause massive bleeding but is much less common than varices in a patient with cirrhosis.
* D) Peptic ulcer disease: While patients with cirrhosis can develop PUD, bleeding esophageal varices are a more specific and likely complication of their underlying liver disease.
